T2 mapping MRI评估甲状腺相关性眼病免疫抑制疗效的初步研究

doi:10.13281/j.cnki.issn.1004-4469.2018.05.004

眼科

T2 mapping MRI评估甲状腺相关性眼病免疫抑制疗效的初步研究

姜虹燕飞鲜军舫艾立坤王雪

100730 首都医科大学附属北京同仁医院，放射科（姜虹、燕飞、鲜军舫），眼科（艾立坤），内分泌科（王雪）

收稿日期:2018-02-08 出版日期:2018-09-25 发布日期:2018-09-18
通讯作者: 燕飞，Email: yanever@163.com

T2 mapping MRI study on immunosuppression therapy of thyroid associated ophthalmopathy

JIANG Hong¹, YAN Fei¹, XIAN Jun-fang¹, AI Li-kun², WANG Xue³

1. Department of Radiology, 2. Department of Ophthalmology, 3. Department of Endocrinology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China

Received:2018-02-08 Online:2018-09-25 Published:2018-09-18
Contact: YAN Fei, Email: yanever@163.com

摘要/Abstract

摘要：

目的探讨T2 mapping MRI评估甲状腺相关性眼病（TAO）免疫抑制疗效的价值。设计前瞻性病例系列。研究对象 74 例经免疫抑制治疗的TAO患者。方法全部患者行冠状面 T2 mapping MRI成像，对图像进行分析。根据患者主要症状、体征及眼外肌功能的改善情况，将免疫抑制治疗效果分为有效和无效，有效分为极好、很好、一般，无效分为无变化、恶化。主要指标 双侧各条眼外肌的T2值，不同疗效患者治疗前maxT2值及治疗前后maxT2变化值。结果免疫抑制疗效极好者18例，很好者13例，一般者11例，无变化者30例，恶化者2例。有效组治疗前maxT2显著大于无效组（P<0.001），治疗后maxT2显著降低（P<0.001），且治疗效果越好，maxT2变化值越大。治疗前maxT2与治疗后maxT2变化值呈显著线性负相关（r=0.643，P<0.0001）。结论眼外肌T2 mapping MRI有助于评估TAO免疫抑制疗效。（眼科， 2018, 27： 339-343）

Abstract:

Objective To evaluate the value of T2 mapping MRI in evaluating immunosuppression therapy of thyroid associated ophthalmopathy (TAO). Design Prospective case series. Participants 74 TAO patients with immunosuppression therapy. Method Coronal T2 mapping MRI was performed. According to the changes of main symptoms, sign and extraocular muscles (EOMs) function, the outcomes of immunosuppression therapy were divided into effectiveness and non-effectiveness. Effectiveness included excellent, well and general cases. Non-effectiveness included unchanged and deterioration cases. Main Outcome Measures T2 values of EOMs and the maxT2 changes. Results The treatment effect was excellent, well, general, unchanged and deteriorated in 18, 13, 11, 30 and 2 cases respectively. The maxT2 was significantly higher in effective group than in non-effective group (P<0.001). MaxT2 value decreased significantly after treatment (P<0.001). Correlation analysis revealed negative correlation between maxT2 and changes of maxT2 after therapy (r=0.643, P＜0.0001). Conclusions T2 mapping MRI is valuable in evaluation of TAO immunosuppression therapy effect. (Ophthalmol CHN, 2018, 27: 339-343)

Key words: thyroid associated ophthalmopathy, T2 mapping magnetic resonance imaging, immunosuppression therapy

姜虹燕飞鲜军舫艾立坤王雪. T2 mapping MRI评估甲状腺相关性眼病免疫抑制疗效的初步研究[J]. 眼科, doi: 10.13281/j.cnki.issn.1004-4469.2018.05.004.

JIANG Hong1, YAN Fei1, XIAN Jun-fang1, AI Li-kun2, WANG Xue3. T2 mapping MRI study on immunosuppression therapy of thyroid associated ophthalmopathy[J]. Ophthalmology in China, doi: 10.13281/j.cnki.issn.1004-4469.2018.05.004.

[1]	罗莎王爽李眉刘黎洁信中. ^99mTc-DTPA眼眶 SPECT/CT评价甲状腺相关性眼病活动性[J]. 眼科, 2018, 27(5): 344-348.
[2]	拓秀信中闫钟钰刘云福. CT眼眶结构定量分析在甲状腺相关性眼病活动性评价中的作用[J]. 眼科, 2018, 27(5): 333-337.
[3]	李眉燕飞. 医学影像学评估甲状腺相关性眼病活动度的价值[J]. 眼科, 2018, 27(5): 321-324.
[4]	周立萍李佳刘明明袁洪峰. 糖皮质激素不同给药方式治疗中重度甲状腺相关性眼病的Meta分析[J]. 眼科, 2018, 27(4): 269-275.
[5]	鲍春丽李婷孙斌 . 儿童甲状腺相关性眼病的临床特点及眼眶显像在其诊断中的应用[J]. 眼科, 2016, 25(6): 366-370.
[6]	孙斌. 生长抑素类似物眼眶显像在甲状腺相关性眼病诊疗中的应用[J]. 眼科, 2016, 25(6): 361-364.
[7]	周晓晴顾燕华张韵马晓晔魏锐利. 免疫抑制剂冲击治疗对甲状腺相关性眼病患者眼表的影响[J]. 眼科, 2016, 25(1): 40-44.
[8]	艾立坤胡依博吴怡满凤媛王雪. 甲状腺相关性眼病提上睑肌的MRI表现[J]. 眼科, 2014, 23(5): 326-331.
[9]	胡依博, 艾立坤, 吴怡, 顼晓琳, 陈雪. 甲状腺相关性眼病眶内组织的病理改变[J]. 眼科, 2014, 23(2): 130-134.
[10]	罗莎, 王雪, 刘黎洁, 李眉 . ^99mTc-奥曲肽SPECT/CT对活动期甲状腺相关性眼病治疗的效果评价[J]. 眼科, 2013, 22(5): 309-312.
[11]	燕飞, 李眉. 重视医学影像学在眼外肌麻痹病因诊断中的价值[J]. 眼科, 2013, 22(5): 289-291.

T2 mapping MRI评估甲状腺相关性眼病免疫抑制疗效的初步研究

T2 mapping MRI study on immunosuppression therapy of thyroid associated ophthalmopathy

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 11

编辑推荐

Metrics

本文评价